Biotron Ltd
ASX:BIT
Biotron Ltd
Total Equity
Biotron Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Total Equity
AU$551.9k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-18%
|
|
|
Immutep Ltd
ASX:IMM
|
Total Equity
AU$143.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
34%
|
CAGR 10-Years
19%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$597.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Total Equity?
Total Equity
551.9k
AUD
Based on the financial report for Jun 30, 2025, Biotron Ltd's Total Equity amounts to 551.9k AUD.
What is Biotron Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-18%
The average annual Total Equity growth rates for Biotron Ltd have been -20% over the past three years , -40% over the past five years , and -18% over the past ten years .
